Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $0.97, $0.15 better than the analyst estimate of $0.82. Revenue for the quarter came in at $341.2 million versus the consensus estimate of $327.96 million.

Charles River Laboratories sees FY2014 EPS of $3.25-$3.35, versus prior guidance of $3.15-$3.25 and the consensus of $3.21.

James C. Foster, Chairman, President and Chief Executive Officer, said, “We are very pleased with the second-quarter performance, which is one of the strongest we have ever reported. Double-digit sales growth for the EMD, Biologics, and safety assessment businesses, and the acquisition of Argenta and BioFocus, drove mid-teens revenue growth in the quarter. Leverage from higher sales and our efficiency initiatives combined to generate a 33% increase in non-GAAP earnings per share. As a result, we are increasing our 2014 non-GAAP earnings guidance to a range of $3.25 to $3.35.”

“We are continuing our focus on targeted sales efforts, which have been particularly successful with the mid-tier clients. And now that we have broadened our early-stage portfolio with the addition of early discovery capabilities, we are engaging in expanded discussions with existing clients and reaching potential clients who are interested in outsourcing entire drug discovery and development programs to a single provider. We believe these discussions will result in expanded and new strategic relationships across our global, mid-tier, and academic clients,” Mr. Foster concluded.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.